Human Insulin Market Poised to Surge from USD 27.0 Billion

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Human Insulin Market Poised to Surge from USD 27.0 Billion in 2015 to USD 43.6 Billion, Globally by 2021 – ZionMarketResearch.Com

Sarasota, FL, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Zion Research has published a new report titled “ Human Insulin Market  by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application -Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021” According to the report, the global Human Insulin market accounted for USD 27.00 billion in 2015 and is expected to reach USD 43.6 billion by 2021, growing at a CAGR of around 8.3% between 2016 and 2021. 

Insulin is necessary for normal carbohydrate, protein, and fat metabolism. People with type 1 diabetes mellitus do not produce enough of this hormone to sustain life and therefore depend on exogenous insulin for survival. In contrast, individuals with type 2 diabetes are not dependent on exogenous insulin for survival. However, over the time, many of these individuals will show decreased insulin production, therefore requiring supplemental insulin for adequate blood glucose control, especially during times of stress or illness. This position statement addresses issues regarding the use of conventional insulin administration (i.e., via syringe or pen with needle and cartridge) in the self-care of the individual with diabetes.

Browse 13 Market Tables and 25 Figures spread through 110 Pages and an in-depth TOC on "Human Insulin Market - Global Size, Shares, Trends, Segment & Forecast to 2021”

Get Sample Research Report at https://www.zionmarketresearch.com/sample/hum...lin-market

The global human insulin market is expected to witness significant growth during the forecast period. This growth is attributed due to increasing risk of diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. An insulin regimen is often required in the treatment of gestational diabetes and diabetes associated with certain conditions or syndromes (e.g.pancreatic diseases, drug- or chemical-induced diabetes, endocrinopathies, insulin-receptor disorders, certain genetic syndromes). In all instances of insulin use, the insulin dosage must be individualized and balanced with medical nutrition therapy and exercise.

Drugs segment dominated the human insulin market across globe in 2015 followed by drug delivery device due to its excess demand, rising proportion of aging population in developed countries, growing research & development for drug discovery & development, increasing market accessibility of generic products worldwide, and rising government initiatives.

Browse the full " Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021 " report at  https://www.zionmarketresearch.com/report/hum...lin-market

In terms of drugs, biosimilars drugs were expected to account for the largest market share of the human insulin market in upcoming forecast period. Demand for biosimilar drugs is strong in both developed and developing countries due to its low cost therapy. This is driven by the need for the best valuable treatment, which can often be expensive. Biosimilar insulin drug may offer a less-costly alternative to existing human insulin biologics.

In terms of revenue, North America held the largest share in the global human insulin market in 2015 and is set to continue to dominate the world human insulin market place in the upcoming forecast period. This growth is mainly attributed to the owing to high prevalence of diabetes, technological advances in effective insulin delivery and government support in this region. The rising numbers of pharmaceutical companies coupled with advanced technology are some of the key factors that are expected to fuel the growth of market in this region.

Europe held the second largest share in the global insulin market in terms of revenue. European countries like Germany, France and Italy are the major markets of human insulin. The prevalence of type 1 diabetes is rising in all European countries, particularly in Scandinavia and the UK. Insulin therapy in Europe is strongly influenced by the results of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), both of which showed the importance of tight metabolic control in patients with diabetes.

Asia-Pacific is expected to be the fastest growing market for human insulin production, development, and distribution during forecast periods. Furthermore, Asia-Pacific countries are considered to be the profitable ones for investors to invest in for manufacturing and clinical activities of pipeline and existing human insulin products. Major players enter the Asian market with the purpose to work together with various CMO and CRO existing in this region that is expected to foster the development of human insulin at lower cost in the near future.

Related Latest Reports:

The demand for human insulin would be on the rise in the coming years due to the high prevalence rate of diabetes as well as low price of human insulin. Countries such as China, India, Japan, and Korea are expected to offer potential growth opportunities to human insulin market. China is estimated to be the fastest growing market for human insulin market. This trend is expected to continue within the forecast period. UAE and Brazil may emerge as lucrative markets for human insulin market in the coming years.

Key market players of human insulin market include Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, Ypsomed AG and Wockhardt.

This report segments the global human insulin market as follows:

Human Insulin Market: Product Segment Analysis

  • Drugs
    • Insulin Analogs and Biosimilars
    • Human Insulin Biologics
  • Drug Delivery Devices
    • Pens
    • Pen Needles
    • Syringes

Human Insulin Market: Application Segment Analysis

  • Insulin dependent diabetes mellitus (Type 1)
  • Non-Insulin dependent diabetes mellitus (Type 2)

Human Insulin Market: Regional Segment Analysis

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Browse Press Release at https://www.zionmarketresearch.com/news/globa...lin-market

About Us

Zion Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Zion Market Research experienced team of Analysts, Researchers, and Consultants uses proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each Zion Market Research syndicated research report covers a different sector — such as pharmaceuticals, chemical, energy, food and beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports strive to serve the overall research requirement of clients.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research

Follow Us Twitter: https://twitter.com/zion_research

Latest Pharmaceutical Research Reports: https://www.zionmarketresearch.com/category/pharmaceutical

Contact US: Joel John 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 113

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 86

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 64

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 77

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 426

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 133

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 73

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading

Top 5 Most Recently Viewed Articles

RPM International Reports Strong Sales Amid Tariff Challenges

Updated Category News Views 147

RPM International Achieves Notable Sales Growth RPM International Inc. (NYSE: RPM) has recently announced a significant financial performance, showcasing record sales during its first fiscal quarter. The company reported an impressive $2.11 billion in sales, marking a 7.4% increase from $1.97 billion in the same quarter of the previous year, surpassing estimates of $2.057...

Continue Reading
Growing CRM Market Driven by AI: Insights for 2024-2028

Updated Category News Views 122

CRM Market Shift: Embracing AI and SME Adoption The global CRM market is experiencing significant growth, projected to increase by USD 60 billion between 2024 and 2028. This robust expansion reflects a compound annual growth rate (CAGR) of 10.23%. A major contributor to this trend is the growing acceptance of customer relationship management (CRM) systems among small and...

Continue Reading
Rexel Announces Key Changes in Executive Leadership Team

Updated Category News Views 586

Leadership Appointments at Rexel Rexel, a leader in the multichannel distribution of energy solutions, has recently made significant appointments to its Group Executive Committee. These changes signify the company's commitment to innovation and strategies that drive transformation in their markets. New Responsibilities and Key Appointments A notable change is the...

Continue Reading
Strike Performance Footwear: Innovation for Passionate Anglers

Updated Category News Views 141

Revolutionizing Angling Footwear with Strike The world of fishing is about to be transformed with the introduction of Strike, a performance footwear brand designed by anglers, for anglers. This innovative brand stands out for its commitment to sustainability without compromising on comfort and performance. Whether you are on the water, on deck, or by the shore, Strike...

Continue Reading
Ascentage Pharma Plans 2025 Mid-Year Results Release and Update

Updated Category News Views 216

Ascentage Pharma to Release 2025 Interim Results Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) is on the verge of a significant update for stakeholders and investors. The company, recognized for its commitment to addressing unmet needs in cancer treatment, has announced plans to unveil their unaudited interim results for the first six months of 2025....

Continue Reading